PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
暂无分享,去创建一个
A. Lenzi | E. Jannini | M. Motta | E. Di Cesare | V. Tombolini | M. Piccolella | G. Gravina | C. Festuccia | P. Muzi | F. Marampon | A. Mancini | P. Negri‐Cesi
[1] Y. Chou,et al. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. , 2011, Cancer letters.
[2] E. Ricevuto,et al. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. , 2011, International journal of oncology.
[3] B. Zani,et al. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. , 2011, Endocrinology.
[4] Q. Guo,et al. The suppression of prostate LNCaP cancer cells growth by Selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. , 2011, Biomaterials.
[5] M. Shiota,et al. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. , 2011, Current cancer drug targets.
[6] D. Tindall,et al. Androgen receptor signaling in prostate cancer development and progression , 2011, Journal of carcinogenesis.
[7] R. deVere White,et al. Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3 , 2011, Clinical Cancer Research.
[8] W. V. van IJcken,et al. Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines , 2011, PloS one.
[9] P. Stattin,et al. Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.
[10] Xiaoping Zhou,et al. Characterization of Androgen Receptor Structure and Nucleocytoplasmic Shuttling of the Rice Field Eel* , 2010, The Journal of Biological Chemistry.
[11] N. Sharifi. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer , 2010, Expert opinion on investigational drugs.
[12] M. Cronauer,et al. Inhibition of glycogen synthase kinase‐3β promotes nuclear export of the androgen receptor through a CRM1‐dependent mechanism in prostate cancer cell lines , 2010, Journal of cellular biochemistry.
[13] J. Alumkal,et al. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6 , 2009, Proceedings of the National Academy of Sciences.
[14] L. Borsu,et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.
[15] R. Watson,et al. The epigenome as a therapeutic target in prostate cancer , 2010, Nature Reviews Urology.
[16] M. Jeffers,et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer , 2008, International journal of cancer.
[17] D. McDonnell,et al. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation , 2008, Molecular Cancer Therapeutics.
[18] Sarat Chandarlapaty,et al. SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers , 2008, Clinical Cancer Research.
[19] R. Vessella,et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. , 2007, Endocrine-related cancer.
[20] Zhou Wang,et al. The Hsp90 inhibitor, 17‐AAG, prevents the ligand‐independent nuclear localization of androgen receptor in refractory prostate cancer cells , 2007, The Prostate.
[21] A. Valentini,et al. Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways , 2006, Anti-cancer drugs.
[22] M. Sehested,et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.
[23] Minoru Yoshida,et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.
[24] F. Saatcioglu,et al. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells , 2005, The Prostate.
[25] C. G. Korkmaz,et al. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. , 2004, The Journal of endocrinology.
[26] Hing Y Leung,et al. Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.
[27] D. Neal,et al. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.
[28] D. Leroith,et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.
[29] P. Finn,et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.
[30] Angie Rizzino,et al. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. , 2002, Carcinogenesis.
[31] L. Ossowski,et al. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. , 2001, Cancer research.
[32] R. Dahiya,et al. Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.
[33] Jian Zhang,et al. Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro , 2001, The Prostate.
[34] N. Hay,et al. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.
[35] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[36] H. Xu,et al. The Hsp 90 inhibitor , 17-AAG , prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells , 2012 .
[37] D. Tindall,et al. Androgen action during prostate carcinogenesis. , 2011, Methods in molecular biology.
[38] J. Bradner,et al. INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS , 2005 .
[39] F. Dequiedt,et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.
[40] K. Ito,et al. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. , 1991, Receptor.